Table 2 Demographic and clinical characteristics of patients
CE interviews (n = 41) | CD interviews (n = 18) | |
|---|---|---|
Gender, n (%) | ||
Male | 2 (5) | 1 (6) |
Female | 39 (95) | 17 (94) |
Mean age, years (SD) | 47.7 (12.6) | 50.8 (14.4) |
Ethnicity, n (%) | ||
Caucasian | 22 (55) | 7 (39) |
African American | 10 (25) | 11 (61) |
Latino/Hispanic | 5 (12) | 0 |
Other | 2 (5) | 0 |
Asian | 1 (2) | 0 |
Marital status, n (%) | ||
Married | 16 (39) | 5 (28) |
Lives with partner | 0 | 1 (6) |
Widowed/divorced/separated | 8 (19) | 6 (33) |
Single/never married | 17 (42) | 5 (28) |
No response | 0 | 1 (6) |
Employment, n (%) | ||
Not currently working for pay | 11 (27) | 2 (11) |
Working full time | 11 (27) | 4 (22) |
Working part time | 1 (2) | 2 (11)a |
Retired | 6 (15) | 5 (28) |
Disabled | 0 | 5 (28) |
Other | 12 (29) | 0 |
Mean time since SLE diagnosis, years (SD)b | 8.56 (8.13), range < 1–35 (n = 38) | 11.28 (10.38), range 1–38 (n = 14) |
Mean SELENA-SLEDAIc (SD) | 6.02 (3.60) (n = 37) | 6.06 (2.53) |
Mean SLICC/ACR damage indexc (SD) | 5.96 (1.74) (n = 25) | 6.00 (1.83) (n = 10) |
SLE severity, n (%) | ||
Mild | 22 (54) | 9 (50) |
Moderate | 18 (44) | 9 (50) |
Severe | 1 (2) | 0 |
Current SLE treatmentd, n (%) | ||
Hydroxychloroquine | 29 (71) | 14 (78) |
Corticosteroids | 19 (46) | 10 (56) |
NSAIDs | 7 (17) | 2 (11) |
Belimumab | 6 (15) | 2 (11) |
Methotrexate | 4 (10) | 3 (17) |
Concomitant conditione, n (%) | ||
Fibromyalgia | 10 (24) | 4 (22) |
Osteopenia/osteoporosis | 9 (22) | 5 (28) |
Anxiety | 9 (22) | 3 (17) |
Hypertension | 8 (20) | 4 (22) |
Depression | 7 (17) | 2 (11) |
Rheumatoid arthritis | 5 (12) | 1 (6) |
Asthma | 4 (10) | 2 (11) |
Osteoarthritis | 4 (10) | 4 (22) |
Sjögren’s syndrome | 4 (10) | 2 (11) |
Lupus nephritis | 3 (7) | 4 (22) |
Hyperlipidemia/hypercholesterolemia | 2 (5) | 3 (17) |
Vasculitis | 2 (5) | 2 (11) |
Other renal diseases (non-lupus)/ESRD | 1 (2) | 2 (11) |
Congestive heart failure | 0 | 2 (11) |